- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib for the treatment of mantle cell lymphoma
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 7, Issue 5, Pages 521-531
Publisher
Informa UK Limited
Online
2014-08-27
DOI
10.1586/17474086.2014.951323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ibrutinib in B-cell Lymphomas
- (2014) Kami Maddocks et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Ibrutinib: First Global Approval
- (2014) Fiona Cameron et al. DRUGS
- Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
- (2014) Sabine Ponader et al. JOURNAL OF CLINICAL ONCOLOGY
- Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management
- (2013) Julie M. Vose AMERICAN JOURNAL OF HEMATOLOGY
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
- (2013) Amin Aalipour et al. BRITISH JOURNAL OF HAEMATOLOGY
- Current and Emerging Therapies in Mantle Cell Lymphoma
- (2013) L. Kyle Brett et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Indolent mantle cell lymphoma
- (2013) Eric D. Hsi et al. LEUKEMIA & LYMPHOMA
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- Toward New Treatments for Mantle-Cell Lymphoma?
- (2013) Emanuele Zucca et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
- (2013) Valkal Bhatt et al. PHARMACOTHERAPY
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-cell receptor signaling as a driver of lymphoma development and evolution
- (2013) Carsten U. Niemann et al. SEMINARS IN CANCER BIOLOGY
- Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
- (2012) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Guidelines for the investigation and management of mantle cell lymphoma
- (2012) P. McKay et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
- (2012) Christian H. Geisler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
- (2012) Michael Y. Choi et al. CANCER JOURNAL
- Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways
- (2012) Tomoko Yasuhiro et al. CANCER RESEARCH
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
- (2012) A. Navarro et al. CANCER RESEARCH
- A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
- (2012) C. Renner et al. HAEMATOLOGICA
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Molecular pathogenesis of mantle cell lymphoma
- (2012) Pedro Jares et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
- (2011) A. Hadzidimitriou et al. BLOOD
- Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
- (2011) Francesco Merli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
- (2011) Chiara Pighi et al. CELLULAR ONCOLOGY
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
- (2010) P. Perez-Galan et al. BLOOD
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidylinositol 3'-Kinase Catalytic Subunit Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
- (2009) A. Psyrri et al. CLINICAL CANCER RESEARCH
- Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma
- (2009) Heather E. Eve et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
- (2009) Peter Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
- (2008) Yuhong Zhou et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now